Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 10/20 | 0.68 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.68 |
| ▸ | PDE8A | O60658 | 3/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | SCARB1 | Q8WTV0 | 4/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837852 | 1.00 | PDE7A (0.68) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL30837849 | 0.90 | PDE7A (0.68) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL100891 | 0.90 | PDE7A (0.68) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL100092 | 0.88 | PDE7A (0.65) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL100342 | 0.87 | PDE7A (0.64) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL99919 | 0.86 | PDE7A (0.78) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL100132 | 0.86 | PDE7A (0.73) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL30837993 | 0.86 | PDE7A (0.73) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL100125 | 0.86 | PDE7A (0.85) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL100794 | 0.85 | PDE7A (0.78) | PDE7APDE7BPDE8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205593-B1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2016-01-13 | — | — | EP | claimed |
| EP-2416777-B1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI SA (FR) | 2014-11-12 | — | — | EP | claimed |
| US-8846654-B2 | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | SANOFI (FR) | 2014-09-30 | — | — | US | claimed |
| EP-2411009-B1 | Therapeutic uses of quinazolinedione derivatives | SANOFI SA (FR) | 2013-03-20 | — | — | EP | claimed |
| US-8242126-B2 | Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2012-08-14 | — | — | US | claimed |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-07-19 | — | — | US | claimed |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| US-12037399-B2 | Anti-Dectin-1 antibodies and methods of use thereof | DREN BIO, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2023196786-A1 | ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF | DREN BIO, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196785-A1 | MULTISPECIFIC BINDING PROTEINS THAT BIND DECTIN-1 AND CD20 AND METHODS OF USE THEREOF | DREN BIO, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-116724054-A | anti-Dectin-1 antibodies and methods of use thereof | 德伦生物公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-4225373-A1 | ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF | Dren Bio, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20090155164-A1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | AMGEN, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-7521048-B2 | TRAIL receptor-2 polypeptides and antibodies | AMGEN INC. (US) | 2009-04-21 | — | — | US | disclosed |
| WO-2009026303-A1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| CN-101300273-A | TRAIL recipient 2 Polypeptides and antibodies | AMGEN INC (US) | 2008-11-05 | — | — | CN | disclosed |
| EP-1922337-A2 | TRAIL RECEPTOR 2 POLYPEPTIDES AND ANTIBODIES | Amgen Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070179086-A1 | Polypeptides and antibodies | AMGEN INC. | 2007-08-02 | — | — | US | disclosed |
| WO-2007027713-A2 | TRAIL RECEPTOR 2 POLYPEPTIDES AND ANTIBODIES | AMGEN INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | PDE7A 5/4885PDE7B 14/4885PDE8A 8/4885 |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | FABP3, SLC5A1, SLC5A2 | PDE7A 1769/4885PDE7B 937/4885PDE8A 2886/4885 |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SLC5A2, SLC5A1, PPARD | PDE7A 1520/4885PDE7B 1364/4885PDE8A 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.